Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure

Amy Arnold, Claudia E. Ramirez, Leena Choi, Luis E. Okamoto, Alfredo Gamboa, André Diedrich, Satish R. Raj, David Robertson, Italo Biaggioni, Cyndya Shibao

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Severely affected patients with autonomic failure require pressor agents to counteract the blood pressure fall and improve presyncopal symptoms upon standing. Previous studies suggest that combination ergotamine and caffeine may be effective in the treatment of autonomic failure, but the efficacy of this drug has not been evaluated in controlled trials. Therefore, we compared the effects of ergotamine/caffeine on seated blood pressure and orthostatic tolerance and symptoms in 12 primary autonomic failure patients without history of coronary artery disease. Patients were randomized to receive a single oral dose of placebo, midodrine (5-10 mg), or ergotamine and caffeine (1 mg and 100 mg, respectively) in a single-blind, crossover study. Blood pressure was measured while patients were seated and after standing for up to 10 minutes, at baseline and at 1 hour post-drug. Ergotamine/caffeine increased seated systolic blood pressure, the primary outcome, compared with placebo (131±19 and 95±12 mmHg, respectively, at 1 hour post-drug; p=0.003 for time effect). Midodrine also significantly increased seated systolic blood pressure (121±19 mmHg at 1 hour post-drug; p=0.015 for time effect versus placebo), but this effect was not different from ergotamine/caffeine (p=0.621). There was no significant effect of either medication on orthostatic tolerance; however, ergotamine/caffeine improved presyncopal symptoms (p=0.034). These findings suggest that combination ergotamine and caffeine elicits a seated pressor response that is similar in magnitude to midodrine, and improves symptoms in autonomic failure. Thus, ergotamine/caffeine could be used as an alternate treatment for autonomic failure, in carefully selected patients without comorbid coronary artery disease.

Original languageEnglish (US)
Article numberArticle 270
JournalFrontiers in Physiology
Volume5 JUN
DOIs
StatePublished - Jan 1 2014

Fingerprint

Blood Pressure
Midodrine
Treatment Failure
Pharmaceutical Preparations
Coronary Artery Disease
Placebos
Single-Blind Method
Placebo Effect
ergotamine drug combination caffeine
Cross-Over Studies

All Science Journal Classification (ASJC) codes

  • Physiology
  • Physiology (medical)

Cite this

Arnold, Amy ; Ramirez, Claudia E. ; Choi, Leena ; Okamoto, Luis E. ; Gamboa, Alfredo ; Diedrich, André ; Raj, Satish R. ; Robertson, David ; Biaggioni, Italo ; Shibao, Cyndya. / Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure. In: Frontiers in Physiology. 2014 ; Vol. 5 JUN.
@article{7b4e0e8ac2f0499681f844907b53af57,
title = "Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure",
abstract = "Severely affected patients with autonomic failure require pressor agents to counteract the blood pressure fall and improve presyncopal symptoms upon standing. Previous studies suggest that combination ergotamine and caffeine may be effective in the treatment of autonomic failure, but the efficacy of this drug has not been evaluated in controlled trials. Therefore, we compared the effects of ergotamine/caffeine on seated blood pressure and orthostatic tolerance and symptoms in 12 primary autonomic failure patients without history of coronary artery disease. Patients were randomized to receive a single oral dose of placebo, midodrine (5-10 mg), or ergotamine and caffeine (1 mg and 100 mg, respectively) in a single-blind, crossover study. Blood pressure was measured while patients were seated and after standing for up to 10 minutes, at baseline and at 1 hour post-drug. Ergotamine/caffeine increased seated systolic blood pressure, the primary outcome, compared with placebo (131±19 and 95±12 mmHg, respectively, at 1 hour post-drug; p=0.003 for time effect). Midodrine also significantly increased seated systolic blood pressure (121±19 mmHg at 1 hour post-drug; p=0.015 for time effect versus placebo), but this effect was not different from ergotamine/caffeine (p=0.621). There was no significant effect of either medication on orthostatic tolerance; however, ergotamine/caffeine improved presyncopal symptoms (p=0.034). These findings suggest that combination ergotamine and caffeine elicits a seated pressor response that is similar in magnitude to midodrine, and improves symptoms in autonomic failure. Thus, ergotamine/caffeine could be used as an alternate treatment for autonomic failure, in carefully selected patients without comorbid coronary artery disease.",
author = "Amy Arnold and Ramirez, {Claudia E.} and Leena Choi and Okamoto, {Luis E.} and Alfredo Gamboa and Andr{\'e} Diedrich and Raj, {Satish R.} and David Robertson and Italo Biaggioni and Cyndya Shibao",
year = "2014",
month = "1",
day = "1",
doi = "10.3389/fphys.2014.00270",
language = "English (US)",
volume = "5 JUN",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Research Foundation",

}

Arnold, A, Ramirez, CE, Choi, L, Okamoto, LE, Gamboa, A, Diedrich, A, Raj, SR, Robertson, D, Biaggioni, I & Shibao, C 2014, 'Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure', Frontiers in Physiology, vol. 5 JUN, Article 270. https://doi.org/10.3389/fphys.2014.00270

Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure. / Arnold, Amy; Ramirez, Claudia E.; Choi, Leena; Okamoto, Luis E.; Gamboa, Alfredo; Diedrich, André; Raj, Satish R.; Robertson, David; Biaggioni, Italo; Shibao, Cyndya.

In: Frontiers in Physiology, Vol. 5 JUN, Article 270, 01.01.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure

AU - Arnold, Amy

AU - Ramirez, Claudia E.

AU - Choi, Leena

AU - Okamoto, Luis E.

AU - Gamboa, Alfredo

AU - Diedrich, André

AU - Raj, Satish R.

AU - Robertson, David

AU - Biaggioni, Italo

AU - Shibao, Cyndya

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Severely affected patients with autonomic failure require pressor agents to counteract the blood pressure fall and improve presyncopal symptoms upon standing. Previous studies suggest that combination ergotamine and caffeine may be effective in the treatment of autonomic failure, but the efficacy of this drug has not been evaluated in controlled trials. Therefore, we compared the effects of ergotamine/caffeine on seated blood pressure and orthostatic tolerance and symptoms in 12 primary autonomic failure patients without history of coronary artery disease. Patients were randomized to receive a single oral dose of placebo, midodrine (5-10 mg), or ergotamine and caffeine (1 mg and 100 mg, respectively) in a single-blind, crossover study. Blood pressure was measured while patients were seated and after standing for up to 10 minutes, at baseline and at 1 hour post-drug. Ergotamine/caffeine increased seated systolic blood pressure, the primary outcome, compared with placebo (131±19 and 95±12 mmHg, respectively, at 1 hour post-drug; p=0.003 for time effect). Midodrine also significantly increased seated systolic blood pressure (121±19 mmHg at 1 hour post-drug; p=0.015 for time effect versus placebo), but this effect was not different from ergotamine/caffeine (p=0.621). There was no significant effect of either medication on orthostatic tolerance; however, ergotamine/caffeine improved presyncopal symptoms (p=0.034). These findings suggest that combination ergotamine and caffeine elicits a seated pressor response that is similar in magnitude to midodrine, and improves symptoms in autonomic failure. Thus, ergotamine/caffeine could be used as an alternate treatment for autonomic failure, in carefully selected patients without comorbid coronary artery disease.

AB - Severely affected patients with autonomic failure require pressor agents to counteract the blood pressure fall and improve presyncopal symptoms upon standing. Previous studies suggest that combination ergotamine and caffeine may be effective in the treatment of autonomic failure, but the efficacy of this drug has not been evaluated in controlled trials. Therefore, we compared the effects of ergotamine/caffeine on seated blood pressure and orthostatic tolerance and symptoms in 12 primary autonomic failure patients without history of coronary artery disease. Patients were randomized to receive a single oral dose of placebo, midodrine (5-10 mg), or ergotamine and caffeine (1 mg and 100 mg, respectively) in a single-blind, crossover study. Blood pressure was measured while patients were seated and after standing for up to 10 minutes, at baseline and at 1 hour post-drug. Ergotamine/caffeine increased seated systolic blood pressure, the primary outcome, compared with placebo (131±19 and 95±12 mmHg, respectively, at 1 hour post-drug; p=0.003 for time effect). Midodrine also significantly increased seated systolic blood pressure (121±19 mmHg at 1 hour post-drug; p=0.015 for time effect versus placebo), but this effect was not different from ergotamine/caffeine (p=0.621). There was no significant effect of either medication on orthostatic tolerance; however, ergotamine/caffeine improved presyncopal symptoms (p=0.034). These findings suggest that combination ergotamine and caffeine elicits a seated pressor response that is similar in magnitude to midodrine, and improves symptoms in autonomic failure. Thus, ergotamine/caffeine could be used as an alternate treatment for autonomic failure, in carefully selected patients without comorbid coronary artery disease.

UR - http://www.scopus.com/inward/record.url?scp=84904390912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904390912&partnerID=8YFLogxK

U2 - 10.3389/fphys.2014.00270

DO - 10.3389/fphys.2014.00270

M3 - Article

AN - SCOPUS:84904390912

VL - 5 JUN

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

M1 - Article 270

ER -